TG103
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
CSPC Baike (Shandong) Biopharmaceutical Co · Phase 2 · Status n/r · Enrollment 208
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| TG103, 15 mg | n/r | n/r | n/r | n/r | n/r |
| TG103, 22.5 mg | n/r | n/r | n/r | n/r | n/r |
| TG103, 30 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.